<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Camurus Ab — News on 6ix</title>
    <link>https://6ix.com/company/camurus-ab</link>
    <description>Latest news and press releases for Camurus Ab on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 09 Jan 2026 14:43:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/camurus-ab" rel="self" type="application/rss+xml" />
    <item>
      <title>Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly</title>
      <link>https://6ix.com/company/camurus-ab/news/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiztm-for-the-treatment-of-acromegaly</link>
      <guid isPermaLink="true">https://6ix.com/company/camurus-ab/news/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiztm-for-the-treatment-of-acromegaly</guid>
      <pubDate>Fri, 09 Jan 2026 14:43:00 GMT</pubDate>
      <description>Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company&apos;s resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 10 June 2026.</description>
    </item>
    <item>
      <title>Camurus reports positive topline results for CAM2056, semaglutide monthly depot</title>
      <link>https://6ix.com/company/camurus-ab/news/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot</link>
      <guid isPermaLink="true">https://6ix.com/company/camurus-ab/news/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot</guid>
      <pubDate>Mon, 10 Nov 2025 07:44:00 GMT</pubDate>
      <description>Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company&apos;s monthly FluidCrystal® semaglutide formulation, in comparison to weekly semaglutide (Wegovy®)1 in 80 individuals with overweight or obesity. The study showed that CAM2056, given as two biweekly initiation doses followed by two monthly doses, was well tolerated, up to the highest initiation dose, and significantly reduced body weight, hemoglobin</description>
    </item>
    <item>
      <title>Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK</title>
      <link>https://6ix.com/company/camurus-ab/news/camurus-announces-approval-of-oczyesar-for-the-treatment-of-acromegaly-in-the-uk</link>
      <guid isPermaLink="true">https://6ix.com/company/camurus-ab/news/camurus-announces-approval-of-oczyesar-for-the-treatment-of-acromegaly-in-the-uk</guid>
      <pubDate>Thu, 28 Aug 2025 15:36:00 GMT</pubDate>
      <description>Camurus (NASDAQ STO: CAMX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa®, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.1</description>
    </item>
    <item>
      <title>Camurus&apos; Oczyesa® receives marketing authorization for treatment of acromegaly in the EU</title>
      <link>https://6ix.com/company/camurus-ab/news/camurus-oczyesar-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu</link>
      <guid isPermaLink="true">https://6ix.com/company/camurus-ab/news/camurus-oczyesar-receives-marketing-authorization-for-treatment-of-acromegaly-in-the-eu</guid>
      <pubDate>Tue, 01 Jul 2025 09:58:00 GMT</pubDate>
      <description>Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.1</description>
    </item>
    <item>
      <title>Camurus&apos; POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients</title>
      <link>https://6ix.com/company/camurus-ab/news/camurus-positano-study-shows-treatment-effects-with-cam2029-in-polycystic-liver-disease-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/camurus-ab/news/camurus-positano-study-shows-treatment-effects-with-cam2029-in-polycystic-liver-disease-patients</guid>
      <pubDate>Wed, 18 Jun 2025 06:31:00 GMT</pubDate>
      <description>Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase 2b study (NCT05281328), evaluating efficacy and safety of octreotide subcutaneous (SC) depot (CAM2029) in patients with symptomatic polycystic liver disease (PLD).</description>
    </item>
    <item>
      <title>Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins</title>
      <link>https://6ix.com/company/camurus-ab/news/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystalr-incretins</link>
      <guid isPermaLink="true">https://6ix.com/company/camurus-ab/news/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystalr-incretins</guid>
      <pubDate>Tue, 03 Jun 2025 18:16:00 GMT</pubDate>
      <description>Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company (&quot;Lilly&quot;) have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus&apos; FluidCrystal technology. The agreement comprises up to four Lilly proprietary drug compounds.*</description>
    </item>
    <item>
      <title>CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU</title>
      <link>https://6ix.com/company/camurus-ab/news/chmp-recommends-approval-of-oczyesar-for-treatment-of-acromegaly-in-the-eu</link>
      <guid isPermaLink="true">https://6ix.com/company/camurus-ab/news/chmp-recommends-approval-of-oczyesar-for-treatment-of-acromegaly-in-the-eu</guid>
      <pubDate>Fri, 25 Apr 2025 14:20:00 GMT</pubDate>
      <description>Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency&apos;s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for market authorization of Oczyesa®, octreotide subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.1</description>
    </item>
  </channel>
</rss>